Nautilus Biotechnology Expands To San Diego

Jan 26 (Reuters) - CytomX Therapeutics Inc: * CYTOMX THERAPEUTICS ANNOUNCES MILESTONE ACHIEVEMENT IN PROBODY® T-CELL ENGAGING BISPECIFIC (TCB) COLLABORATION WITH ASTELLAS * CYTOMX THERAPEUTICS INC -

Jan 26 (Reuters) - Streamline Health Solutions Inc : * STREAMLINE HEALTH® PARTNER SIGNS NEW CONTRACT TO UTILIZE REVID™ AT CALIFORNIA-BASED MEDICAL CENTER Source text for Eikon: Further company

Jan 26 (Reuters) - Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB ANNOUNCES TRANSCEND CLL 004 TRIAL OF BREYANZI® (LISOCABTAGENE MARALEUCEL) MET PRIMARY ENDPOINT OF COMPLETE RESPONSE RATE IN PATIENTS

By Khushi Mandowara and Leroy Leo (Reuters) - Hospital operators in the U.S. are likely to see a dip in fourth-quarter profits as an ongoing staffing crunch limits their ability to take advantage of

By Khushi Mandowara and Leroy Leo Jan 26 (Reuters) - Hospital operators in the U.S. are likely to see a dip in fourth-quarter profits as an ongoing staffing crunch limits their ability to take

Jan 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Abbott Laboratories, Navient and Tesla on Thursday. HIGHLIGHTS *

Jan 25 (Reuters) - Paragon 28 Inc: * PARAGON 28, INC. ANNOUNCES PRICING OF PUBLIC OFFERING * PARAGON 28 INC SAYS PUBLIC OFFERING OF 6.5 MILLION COMMON SHARES PRICED AT $17.00PER SHARE Source text for

Jan 25 (Reuters) - Genelux Corp: * GENELUX CORPORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING * GENELUX CORP SAYS INITIAL PUBLIC OFFERING OF 2.5 MILLION COMMON SHARES PRICED AT $6.00PER SHARE

Jan 25 (Reuters) - LogicMark Inc: * LOGICMARK, INC. ANNOUNCES CLOSING OF $5.2 MILLION UNDERWRITTEN PUBLIC OFFERING PRICED ABOVE MARKET Source text for Eikon: Further company coverage:

Jan 25 (Reuters) - Know Labs Inc: * KNOW LABS INC - ON JANUARY 23, 2023, PHILLIP A. BOSUA RESIGNED FROM BOARD OF DIRECTORS AND FROM HIS POSITION AS CHIEF EXECUTIVE OFFICER * KNOW LABS INC - ON JAN 23,